Status:
COMPLETED
Investigation of Microbiome-based Prognostical Biomarkers in Patients With Morbid Obesity and Bariatric Surgery
Lead Sponsor:
St. Franziskus Hospital
Collaborating Sponsors:
University of Bonn
Conditions:
Obesity, Morbid
Bariatric Surgery Candidate
Eligibility:
All Genders
18+ years
Brief Summary
Morbid obesity leads to non-alcoholic fatty liver disease (NAFLD), and not all NAFLD cases benefit from weight loss e.g. after bariatric surgery. Our aim is to find out, which intrahepatic factors and...
Eligibility Criteria
Inclusion
- BMI above 40 kg/sqm or
- BMI above 35 kg/sqm and comorbidities related to morbid obesity (e.g. type 2 diabetes, hypertension, coronary heart disease, dyslipoproteinemia, sleep apnea, and others
Exclusion
- BMI below 35 kg/sqm
- no informed consent
- patient not suitable for bariatric surgery (severe psychological disorder, pregnancy, drug abuse, active malignant or other consuming disease
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2021
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT03391401
Start Date
March 1 2018
End Date
July 31 2021
Last Update
October 7 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Bonn
Bonn, Germany, 53127
2
St. Franziskus-Hospital
Cologne, Germany, 50825